Table 2 Hazard ratios (95% CI) for total stroke according to sleep duration.

From: Long Sleep Duration and Risk of Ischemic Stroke and Hemorrhagic Stroke: the Kailuan Prospective Study

 

Sleep duration

<6 h

6–8 h

>8 h

Cases, (%)

265 (3.98)

2800 (3.23)

70 (4.39)

 Model 1 †

0.96 (0.85–1.10)

reference

1.37 (1.08–1.74)

 Model 2 ‡

0.96 (0.84–1.09)

reference

1.37 (1.08–1.74)

 Model 3 §

0.92 (0.81–1.05)

reference

1.29 (1.01–1.64)

 Model 4 ※

0.92 (0.81–1.05)

reference

1.29 (1.01–1.64)

 Sensitivity analysis*

0.92 (0.80–1.05)

reference

1.29 (1.01–1.65)

women

 Cases, (%)

32 (2.89)

292 (1.62)

9 (2.40)

Model 1 †

1.16 (0.80–1.68)

reference

2.27 (1.16–4.43)

Model 2 ‡

1.14 (0.79–1.66)

reference

2.33 (1.19–4.55)

Model3 §

1.09 (0.75–1.59)

reference

1.91 (0.98–3.74)

Model 4 ※

1.09 (0.75–1.60)

reference

1.91 (0.98–3.74)

Sensitivity analysis*

1.03 (0.69–1.53)

reference

2.00 (1.02–3.92)

men

 Cases (%)

233 (4.20)

2508 (3.65)

61 (5.00)

Model 1 †

0.93 (0.82–1.07)

reference

1.31 (1.02–1.69)

Model 2 ‡

0.93 (0.81–1.07)

reference

1.31 (1.02–1.69)

Model 3 §

0.90 (0.79–1.04)

reference

1.24 (0.96–1.61)

Model 4 ※

0.90 (0.78–1.03)

reference

1.24 (0.96–1.60)

Sensitivity analysis*

0.91 (0.79–1.04)

reference

1.24 (0.95–1.61)

  1. CI, confidence interval.
  2. †Model 1 was stratified by hospitals, and adjusted for age and sex.
  3. ‡Model 2 was stratified by hospitals, and adjusted for as model 1 plus marital status, family per member monthly income, education level, smoking status, drinking status, physical activity, and family history of stroke.
  4. §Model 3 was stratified by hospitals, and adjusted for the variables in Model 2 plus body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, hypotensive drug use, lipid-lowering drug use, hypoglycemic drug use, history of myocardial infarction, and snoring status.
  5. ※Model 4 was stratified by hospitals, and adjusted for the variables in Model 3 plus high sensitive C-reactive protein, and atrial fibrillation.
  6. *Adjusted for model 3 and further excluded individuals with myocardial infraction and cancer.
Back to article page